Lifeward initiated with a Buy at Laidlaw

Laidlaw analyst Yale Jen initiated coverage of Lifeward (LFWD) with a Buy rating and $10 price target Lifeward is a commercial stage rehabilitation technology-based medical technology company, the analyst tells investors in a research note. The firm says ReWalk “is likely to be on the cusp of a rapid revenue ramp up” period beginning from 2025, while the shares are “highly undervalued” at the current price.